Bleeding After Menopause: The Canadian Assessment Pathway—and What Else It Could Be

If you notice unexpected bleeding after menopause, contact a clinician. The assessment aims to find where the blood came from and rule out endometrial precancer or cancer. Bleeding can also come from other tissues, so the first step is to report what you saw and any symptoms that came with it.

IN THIS ARTICLE +

1. What counts as postmenopausal bleeding?
2. Bleeding on HRT: first, which regimen are you taking?
3. Why estrogen and progestogen protection belong together
4. The Canadian pathway, in plain language
5. Where the ‘4 mm rule’ fits—and where it does not
6. What it may be other than cancer
7. What to record before the appointment
8. Why a benign biopsy may not be the end
9. Access in Canada
10. Sources and further reading

What counts as postmenopausal bleeding?

Any vaginal bleeding, spotting or blood-stained discharge after 12 months without a natural menstrual period should be reported. Bleeding on menopausal hormone therapy has additional timing and regimen considerations, but persistent, heavy, late-onset or recurrent bleeding still requires assessment. Do not stop prescribed MHT abruptly unless the prescriber advises it; report the bleeding and the exact regimen.

Bleeding on HRT: first, which regimen are you taking?

Noticing blood just as treatment starts to help is a particularly unwelcome surprise. You may have finally slept, stopped overheating in meetings or felt more comfortable in your own body. Now someone is discussing an ultrasound. That does not mean HRT has caused cancer, or that you must inevitably give up treatment. It means the bleeding needs an explanation that fits your treatment and your medical history.

Continuous combined HRT: usually aiming to become bleed-free

Continuous combined treatment supplies estrogen and a progestogen on an ongoing basis. Spotting can occur while the lining adjusts after starting treatment or changing an estrogen dose, delivery method or progestogen. The eventual aim is usually no bleeding. A new bleed after a settled, bleed-free period deserves particular attention; “I’ve been on HRT for years” is useful information, not a reason to dismiss it.

Sequential or cyclical HRT: a planned withdrawal bleed

Sequential treatment supplies estrogen regularly and a progestogen for part of each treatment cycle. A withdrawal bleed around the end of the progestogen phase may be expected. It does not necessarily mean natural ovarian cycles have restarted. Ask your prescriber what pattern your particular schedule is intended to produce. Bleeding outside that pattern, or bleeding that becomes unusually heavy, prolonged or unpredictable, needs review.

When timing changes the plan

Report unexpected bleeding even when treatment was recently started or adjusted. In the British Menopause Society pathway, a clinician may first adjust treatment in someone assessed as low risk whose bleeding begins within six months of starting HRT or around a recent change. First presentation more than six months after starting, or more than three months after changing treatment, generally prompts urgent ultrasound. Heavy or prolonged bleeding and significant cancer risk factors can require earlier investigation regardless of timing. These are clinician-led decisions, not permission to wait six months before making contact.

Keep a timeline of estrogen and progestogen changes, including missed doses, patch interruptions and changes in schedule. A missed dose may help explain bleeding, but cannot prove that nothing else is wrong. If progesterone side effects make the regimen difficult to follow, say so. The most useful conversation is about a tolerable, protective plan, rather than trying to make the medication list look perfect.

Why estrogen and progestogen protection belong together

Systemic estrogen stimulates the endometrium. For most people who still have a uterus, progesterone or another suitable progestogen is needed to limit that stimulation and protect against hyperplasia and cancer. The protection depends on the product, amount, duration and overall estrogen regimen. Too little exposure, including missed prescribed treatment, can matter.

Do not stop progesterone while continuing systemic estrogen without arranging appropriate alternative protection with your prescriber. Equally, increasing progesterone is not the automatic answer to every bleed. A polyp, cervical lesion or another cause will not be diagnosed by changing a hormone dose. Your clinician may investigate and review treatment in parallel. See our Canadian MHT guide for the broader treatment choices.

Low-dose vaginal estrogen is a different treatment, with much lower systemic exposure, and ordinarily does not require a progestogen solely for lining protection. Unexpected bleeding still needs assessment. Fragile tissue or an applicator may be involved, but should not be assumed to be the explanation without review. Tell the clinician about local products as well as systemic hormones.

The Canadian pathway, in plain language

Stage	What may happen	Question being answered
1. Confirm the source	History; medication/MHT review; vulvar, vaginal and speculum examination; cervical screening status; sometimes urine or rectal assessment	Is the blood actually vaginal, and is there a visible lower-tract cause?
2. Assess uterus and endometrium	Transvaginal ultrasound and/or office endometrial biopsy; practice varies by risk and access	Is the lining thin and uniform? Is sampled tissue benign?
3. Investigate focal or unresolved findings	Saline-infusion sonography or hysteroscopy with targeted biopsy/removal	Is there a polyp, submucosal fibroid or area a blind biopsy could miss?
4. Act on pathology	Gynaecology or gynaecologic-oncology referral when hyperplasia/EIN/cancer is found	What treatment and staging are needed?
5. Reassess recurrence	Further evaluation even after an initially reassuring test when bleeding returns	Was a focal lesion missed, or has the clinical picture changed?

Where the ‘4 mm rule’ fits—and where it does not

Ultrasound describes the structure of the uterus and lining; biopsy examines cells in the tissue obtained. A thicker measurement does not diagnose cancer, and a thinner one does not guarantee its absence. Whether the entire lining was seen, its appearance, the bleeding history and individual risk are as important as the number.

The American guidance changed in April 2026. ACOG now recommends both transvaginal ultrasound and endometrial tissue sampling for most patients presenting with postmenopausal bleeding. Ultrasound alone remains an option for selected people with a single episode, a fully visualized lining no thicker than 4 mm, no strongly increased risk factors and reliable access to prompt reassessment if bleeding returns. This replaces the older impression that a measurement of 4 mm or less is routinely enough to end an initial evaluation. Read ACOG’s update.

The BMS pathway for unscheduled bleeding on HRT uses different thresholds when the lining is uniform and fully visualized: 4 mm or less for continuous combined HRT, and 7 mm or less for sequential HRT. A thicker lining leads to endometrial assessment in that pathway. These are investigation thresholds within a complete British clinical pathway, not universal definitions of normal or a Canadian self-triage rule.

Canadian practice depends on local guidance and clinical circumstances. The BC endometrial-cancer guideline, published in 2014, recommends biopsy and ultrasound when cancer is suspected and further assessment of persistent bleeding despite negative tests. It should not be mistaken for a newly issued national HRT algorithm. If you have been offered both tests despite a thin lining, ask which findings and guidance inform that recommendation.

Do not confuse bleeding assessment with an incidental thickened lining in someone who has no bleeding. Canadian recommendations for asymptomatic findings address a different problem. Nor should a postmenopausal thickness cutoff be applied indiscriminately to someone still having natural cycles.

What it may be other than cancer

Possible cause	How it causes bleeding	How it is investigated
Vaginal or endometrial atrophy / GSM	Thin, fragile low-estrogen tissue can tear or spot	Examination; ultrasound/biopsy as appropriate before attributing uterine bleeding
Endometrial or cervical polyp	Fragile focal tissue bleeds intermittently	Ultrasound may suggest it; saline sonography or hysteroscopy is better for focal lesions
Fibroid, especially submucosal	Distorts or irritates the cavity	Ultrasound and sometimes hysteroscopy
MHT-related bleeding	Endometrium responds to regimen, dose, missed progesterone or adjustment period	Exact medication timeline plus appropriate imaging/sampling
Cervical/vulvar/vaginal disease	Inflammation, trauma, polyp, dysplasia or cancer	Direct examination, cervical testing/colposcopy when indicated
Infection or trauma	Inflamed or injured tissue bleeds	History, examination and targeted tests
Urinary or rectal source	Blood is mistaken for vaginal bleeding	Urinalysis, examination or gastrointestinal assessment
Endometrial hyperplasia/EIN	Excess growth, sometimes with atypical cells	Endometrial tissue diagnosis
Endometrial cancer or other malignancy	Abnormal tissue bleeds	Biopsy; hysteroscopy and oncology pathway when confirmed

Most postmenopausal bleeding has a benign explanation; the pathway exists because symptoms alone cannot reliably separate benign causes from cancer.

What to record before the appointment

• Date, colour, amount, duration, whether it recurred and whether bleeding followed sex or exertion.
• Every hormone product: estrogen route/dose, progesterone name/dose/schedule, vaginal estrogen, testosterone and missed doses.
• Anticoagulants, tamoxifen and supplements.
• Pain, discharge, fever, urinary or bowel symptoms and unexplained weight change.
• Last natural period, prior bleeding investigations, cervical screening and relevant family history.
• Risk factors such as diabetes, obesity, Lynch syndrome or prolonged unopposed estrogen exposure.

If sampling is recommended, Inside the Test explains what an office endometrial biopsy can find, what an insufficient sample means and why a blind sample can miss a focal lesion. Use the menopause appointment checklist to bring the bleeding timeline, medication list and your priority questions.

Do not postpone contact while collecting these details. Ask when the investigation should happen, who will communicate results, whom to call if they do not arrive, and what the plan is if bleeding continues after a reassuring result. A recent cervical screening result does not rule out cancer of the uterine lining; cervical cancer and cancers of the vagina or vulva are different possible sources of bleeding.

Why a benign biopsy may not be the end

A blind office biopsy samples tissue well for diffuse disease but may miss a focal polyp or fibroid. If bleeding recurs, the sample was insufficient, ultrasound is irregular, or the lining cannot be adequately visualized, direct cavity assessment may be reasonable. A 2026 joint-society guideline concluded that hysteroscopy with visually directed biopsy has higher diagnostic accuracy than blind sampling for several focal and premalignant conditions.

Bleeding that occurs while using menopausal hormone therapy still needs context: the regimen, timing, duration and individual risk factors all matter. The Canadian overview of menopausal hormone therapy explains why systemic estrogen requires appropriate uterine protection when a uterus is present.

Access in Canada

A family physician, nurse practitioner, walk-in/urgent primary-care clinician or MHT prescriber can begin the workup and refer to gynaecology. Access and ordering rules vary by province and region; some clinics arrange ultrasound first, others biopsy first, and some do both. If you cannot obtain timely primary care, provincial 811 services can help identify appropriate local access, but they do not replace the investigation.

Sources and further reading

• BC guideline: Endometrial Cancer—Diagnosis and Management (2014)
• Investigation of women with postmenopausal uterine bleeding: clinical recommendations
• Visually directed hysteroscopic biopsy guideline (2026)
• Endometrial biopsy: tips, performance and limitations
• Rapid recommendations summarizing the 2024 SOGC asymptomatic-endometrium guideline
• Ontario Health Menopause Quality Standard